

Peixun Zhou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8377375/publications.pdf>

Version: 2024-02-01

7
papers

131
citations

1683934
5
h-index

1719901
7
g-index

7
all docs

7
docs citations

7
times ranked

202
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma. <i>Leukemia</i> , 2022, 36, 781-789.	3.3	20
2	Low BACH2 Expression Predicts Adverse Outcome in Chronic Lymphocytic Leukaemia. <i>Cancers</i> , 2022, 14, 23.	1.7	4
3	Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis. <i>Molecular Cell</i> , 2021, 81, 4059-4075.e11.	4.5	42
4	DAP Kinase-Related Apoptosis-Inducing Protein Kinase 2 (DRAK2) Is a Key Regulator and Molecular Marker in Chronic Lymphocytic Leukemia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7663.	1.8	9
5	Sporadic and endemic Burkitt lymphoma have frequent FOXO1 mutations but distinct hotspots in the AKT recognition motif. <i>Blood Advances</i> , 2019, 3, 2118-2127.	2.5	23
6	Uptake of synthetic Low Density Lipoprotein by leukemic stem cells " a potential stem cell targeted drug delivery strategy. <i>Journal of Controlled Release</i> , 2010, 148, 380-387.	4.8	30
7	Nuclear entrapment of BCR"ABL by combining imatinib mesylate with leptomyacin B does not eliminate CD34+ chronic myeloid leukaemia cells. <i>Leukemia</i> , 2009, 23, 1006-1008.	3.3	3